353 related articles for article (PubMed ID: 15719595)
21. Recent advances in the use of aromatase inhibitors for women with postmenopausal breast cancer.
Chowdhury S; Ellis PA
J Br Menopause Soc; 2005 Sep; 11(3):96-102. PubMed ID: 16157000
[TBL] [Abstract][Full Text] [Related]
22. A roundtable discussion of aromatase inhibitors as therapy for breast cancer.
Allred DC; Baum M; Buzdar AU; Carlson RW; Dowsett M; Elledge RM; Gradishar WJ; Grana G; Howell A; Mamounas EP
Breast J; 2003; 9(3):213-22. PubMed ID: 12752630
[TBL] [Abstract][Full Text] [Related]
23. Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy.
Brodie AH; Mouridsen HT
Am J Clin Oncol; 2003 Aug; 26(4):S17-26. PubMed ID: 12902873
[TBL] [Abstract][Full Text] [Related]
24. Challenges in the endocrine management of breast cancer.
Mouridsen HT; Rose C; Brodie AH; Smith IE
Breast; 2003 Aug; 12 Suppl 2():S2-19. PubMed ID: 14659138
[TBL] [Abstract][Full Text] [Related]
25. An overview of letrozole in postmenopausal women with hormone-responsive breast cancer.
Barnadas A; Estévez LG; Lluch-Hernández A; Rodriguez-Lescure A; Rodriguez-Sanchez C; Sanchez-Rovira P
Adv Ther; 2011 Dec; 28(12):1045-58. PubMed ID: 22068628
[TBL] [Abstract][Full Text] [Related]
26. New aromatase inhibitors in the treatment of advanced breast cancer.
Crucitta E; Lorusso V; Attolico M; Sambiasi D; Mazzei A; De Lena M
Int J Oncol; 2000 Nov; 17(5):1037-41. PubMed ID: 11029510
[TBL] [Abstract][Full Text] [Related]
27. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
[TBL] [Abstract][Full Text] [Related]
28. Recent advances in aromatase inhibitor therapy for breast cancer.
Assikis VJ; Buzdar A
Semin Oncol; 2002 Jun; 29(3 Suppl 11):120-8. PubMed ID: 12138406
[TBL] [Abstract][Full Text] [Related]
29. Emerging role of aromatase inhibitors in the adjuvant setting.
Goss PE
Am J Clin Oncol; 2003 Aug; 26(4):S27-33. PubMed ID: 12902874
[TBL] [Abstract][Full Text] [Related]
30. A decade of letrozole: FACE.
O'Shaughnessy J
Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):67-74. PubMed ID: 17912637
[TBL] [Abstract][Full Text] [Related]
31. Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.
Gil JM; Rubio-Terrés C; Del Castillo A; González P; Canorea F
Clin Transl Oncol; 2006 May; 8(5):339-48. PubMed ID: 16760009
[TBL] [Abstract][Full Text] [Related]
32. New aromatase inhibitors for the treatment of advanced breast cancer in postmenopausal women.
de Jong PC; Blijham GH
Neth J Med; 1999 Aug; 55(2):50-8. PubMed ID: 10474272
[TBL] [Abstract][Full Text] [Related]
33. Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer.
Glück S; Gorouhi F
Am J Health Syst Pharm; 2011 Sep; 68(18):1699-706. PubMed ID: 21880884
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F;
Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983
[TBL] [Abstract][Full Text] [Related]
35. Should aromatase inhibitors replace tamoxifen?
Drug Ther Bull; 2003 Aug; 41(8):57-9. PubMed ID: 12966738
[TBL] [Abstract][Full Text] [Related]
36. [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
van Nes JG; Seynaeve C; van de Velde CJ; Nortier JW
Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2863-9. PubMed ID: 17319217
[TBL] [Abstract][Full Text] [Related]
37. A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
Dodwell D; Vergote I
Cancer Treat Rev; 2005 Jun; 31(4):274-82. PubMed ID: 15908126
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
Grana G
J Surg Oncol; 2006 Jun; 93(7):585-92. PubMed ID: 16705732
[TBL] [Abstract][Full Text] [Related]
39. Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole--of clinical importance?
Geisler J
Br J Cancer; 2011 Mar; 104(7):1059-66. PubMed ID: 21364577
[TBL] [Abstract][Full Text] [Related]
40. Anastrozole.
Cuzick J
Drugs Today (Barc); 2005 Apr; 41(4):227-39. PubMed ID: 16034487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
